With the staggering success of Win-Medicare, Mr. Umesh K. Modi felt the need to expand his pharmaceutical business further. And was born Modi–Mundipharma in 1990. It is a 50:50-joint venture between the privately held Mundipharma Group of Switzerland (known as Purdue Pharma in USA and Napp Laboratories in UK) and Mr. Umesh K. Modi. One of the largest, privately held pharmaceutical company in India today, it is ranked 8th among the multinational pharmaceutical corporations in India and 35th among the total of multinational and Indian pharmaceutical companies in India (Source: ORG IMS MAT DEC 10). The Company has a robust team totaling 1500 marketing and sales network professionals. It is effectively represented in the domestic and International markets including Asian, East African, Middle East markets & CIS Countries.

A rapidly growing pharmaceuticals company, Modi-Mundipharma draws its primary strength from sound research and development as well as existing formulations of the Mundipharma group of companies, world wide. Modi-Mundipharma offers world renowned formulations in various therapeutic segments, encompassing cardiology, respiratory, gynaecology, pain, heart diseases and other chronic therapy segments.

RESPIRATORY	View Product Portfolio
CARDIOVASCULARS	View Product Portfolio
UROLOGICALS	View Product Portfolio
GYNAECOLOGICALS	View Product Portfolio
ANALGESICS/NSAIDs	View Product Portfolio
NUTRITIONAL	View Product Portfolio
OTHERS	View Product Portfolio

Medical fraternity, across the length and breadth of India, perceive Modi-Mundipharma to be a pharmaceutical company that offers long acting formulations in specialised therapeutic segments. It has reached this position with consistent exposure of the brand benefits derived from Continus controlled drug delivery, the  differentiated and unique New Drug Delivery System (NDDS) endorsed by medical practitioners across 70 countries world over.

A research & development collaboration agreement has been signed between Modi-Mundipharma, India and Mundipharma Laboratories GMBH under which Modi-Mundipharma will undertake development of product formulations for Purdue Pharma.

The focus of Modi-Mundipharma is to continue offering state-of-the-art and latest high-tech pharmaceutical solutions through introduction of differentiated products in the field of respiratory, pain and heart diseases. It is effectively represented in the domestic and South Asian markets.

Modi-Mundipharma markets:

• Largest Nitrate brand in India
• Second Largest O.S. Tramadol brand in India
• Largest Plain O.S. Tramadol brand in India

Under its wing Modi-Mundipharma group has:

• Win-Medicare Pvt. Ltd.; a subsidiary.
• Win Healthcare; OTC arm of Win Medicare.
• Mundipharma (Bangladesh) Pvt. Ltd.; a wholly owned subsidiary. (1st international pharma plant of the group)
• Modi-Revlon Pvt. Ltd., under which is
  • # Revlon Trading Bangladesh Pvt. Ltd.; a wholly owned subsidiary of Modi-Revlon.
  • # Revlon Lanka (Pvt.) Ltd.; a wholly owned subsidiary of Modi-Revlon.
  • # Kamakhya Cosmetics & Pharmaceuticals Pvt.Ltd.
• Modi Omega; JV Collaboration between Modi Mundipharma & Omega.

Its licensing partners are:

• Merz Pharmaceuticals, Germany
  In licensing arrangement with Merz & Co. GMBH, Germany, for marketing:
  • HepaMerz^TM, for hepatotherapeutics;
  • Axura^® for Alzheimer’s disease and
  • Contractubex^® & Mederma^® for treatment of scars.
• Tillotts Pharma AG, Switzerland
  In licensing arrangement with Tillotts Pharma AG, Switzerland, for marketing:
  • Asacol®, a product for management of ulcerative colitis.
• IBSA - Institut Biochimique SA, Switzerland
  In licensing arrangement with IBSA - Institut Biochimique SA, Switzerland, for marketing:
  • Corion^®, Pregnorm^®, and Gonatrop^® F, the infertility management range.
• Pierre Fabre France
  In licensing arrangement with Pierre Fabre, France, for marketing:
  
  • Eludril®
  • Arthrodont®
  • Pansoral®
  • Elugel^tm
  • Elgydium®
• Sigma Tau, Italy
  In licensing arrangement with Sigma Tau, Italy, for marketing:
  • Carnitor®, for managing primary & secondary carnitine deficiency states.
• Zambon,Italy
  In licensing arrangement with Zambon, Italy, for marketing:
  • Fluimicil® - For Respiratory Portfolio
  • Monurol® - For Managing UTI.
• Norgine UK
  In licensing arrangement with Norgine, UK, for marketing:
  • Movicol®
  • Moviprep®
• TRIGO Care International GMbH, Germany
  In licensing arrangement for marketing:
  • Diagnopad™ – Diagnostic kit for early detection of Diabetic Neuropathy.
• Orion, Finland
  In licensing arrangement with Orion, Finland for marketing:
  • Divigel® – For Hormone replacement Therapy.